Medical Xpress August 20, 2024
Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows.
The three-year-long trial, funded by the drugs’ maker, Eli Lilly, also found “sustained weight loss through the treatment period, with adults on the 15-milligram [mg] dose experiencing a 22.9% average decrease in body weight compared to 2.1% for placebo,” the company said in a news release issued Tuesday.
“These data reinforce the potential clinical benefits of long-term therapy for people living with obesity and prediabetes,” Dr. Jeff Emmick, senior vice president of product development at Lilly, said in the release.
Tirzepatide is a competitor GLP-1 drug to semaglutide,...
Today's Sponsors
Today's Sponsor